Author

Pablo Nenclares

Institute of Cancer ResearchORCID 0000-0002-1750-3179Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Alan A. MelcheriD· 3 shared Anton PatrikeeviD· 3 shared Emmanuel Christian PatiniD· 3 shared Joan KyulaiD· 3 shared Kevin Joseph HarringtoniD· 3 shared Malin PederseniD· 3 shared Masahiro OnoiD· 3 shared Shane FooiD· 3 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Alan A. MelcherORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 18, 2026

Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8+ T-cell clonal dominance in head and neck cancer

Charleen Chan Wah Hak, Anton Patrikeev, Antonio Rullan…·Alan A. Melcher

This study shows that chemoradiotherapy (CRT) in head and neck cancer promotes clonal dominance of progenitor-exhausted CD8+ T-cells compared to radiotherapy alone.

DOI 10.64898/2026.03.10.710795

mousescRNA-seq

𝕏 PostBluesky

ImmunologyNature CommunicationsPeer-reviewedAug 12, 2024

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

Emmanuel Christian Patin, Pablo Nenclares, Charleen Chan Wah Hak…·Kevin Joseph Harrington

This study combines ATR inhibition with radiotherapy and immune checkpoint blockade to enhance antitumour immunity in HNSCC preclinical models.

22 citations

mouseproteomics

𝕏 PostBluesky

Cancer BiologyJournal for ImmunoTherapy of CancerPeer-reviewedJul 1, 2024

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling.

Edward John Lloyd Armstrong, Matthew Kin-Liang Chiu, Shane Foo…·Victoria A. Jennings

This study shows that combining oncolytic Maraba virus with PD-1 blockade overcomes resistance in advanced melanoma with a cold tumor microenvironment.

16 citations

mousebulk RNA-seq

𝕏 PostBluesky